Dermatology Times

4 days ago | dermatologytimes.com | Marie Bosslett

The National Psoriasis Foundation (NPF) has recently expanded its Seal of Recognition program to include prescription drugs approved by the US Food and Drug Administration (FDA), making Arcutis Biotherapeutics’ Zoryve (roflumilast) the first therapy to achieve this recognition.1 The categorization includes the cream 0.3% and topical foam 0.3% versions of roflumilast.

4 days ago | dermatologytimes.com | Brian Nowosielski

Researchers discovered a notable correlation between atopic dermatitis and dementia, according to data published in Acta Dermato-Venereologica.1 Despite randomization analysis failing to identify a causal relationship between the 2 conditions, study results were able to inform future exploration into this correlation.

5 days ago | dermatologytimes.com | Maddi Hebebrand |Marie Bosslett

To stay informed with the latest conference insights, subscribe to receive our eNewsletters. Discover expert insights and practice management tips at the Fall Clinical PA/NP Conference in Orlando, featuring top dermatology professionals.

5 days ago | dermatologytimes.com | Emma Andrus |Adam Friedman

In a recent interview with Dermatology Times, Adam Friedman, MD, FAAD, professor and chair of dermatology at the George Washington University School of Medicine and Health Sciences, shared insights from a new study examining how US dermatologists screen for and manage lichen planus.1 The cross-sectional study, published in Dermatology and Therapy,2 surveyed more than 400 dermatologists and uncovered wide variation in clinical practices, especially regarding screening for comorbidities and...

5 days ago | dermatologytimes.com | Emma Andrus

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Dermatology Times has compiled a list of dermatological meetings taking place during the month of June. Discover essential business metrics for PAs in dermatology, empowering practice ownership and driving sustainable growth through data-driven strategies. Recludix advances REX-8756, a first-in-class oral STAT6 inhibitor, showing promise for safer, targeted treatment of type 2 inflammatory skin diseases.